$56.89▴ 4.12%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Undervalued
Trading about 11% below our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Exelixis, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days1 article
0 bullish1 neutral0 bearish
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight